Reports
Sale
Global Hyperphosphatemia Therapeutics Market Share, Trends, Analysis: By Product type: Sevelamer, Calcium-Based Phosphate Blinders, Iron-based Phosphate Binders, Aluminium-based Phosphate Blinders; By Form; By Distribution Channels; Regional Analysis; Competitive Landscape; Key Trends and Developments in the Market; 2024-2032
Global Hyperphosphatemia Therapeutics Market Outlook
The global hyperphosphatemia therapeutics market would likely grow at a CAGR of 5.4% during 2024-2032. Asia, North America and Europe are likely to be key markets.
Global Market Likely to be Driven by Need for Effective Treatment for Hyperphosphatemia
Hyperphosphatemia refers to serum phosphate concentration > 4.5 mg/dL (> 1.46 mmol/L). Metabolic or respiratory acidosis, Chronic kidney disease, and hypoparathyroidism could be possible causes. Serum phosphate measurement is carried out for diagnosis. Treatment may comprise limited intake of phosphate and taking phosphate-binding antacids, like calcium carbonate.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Reduced renal excretion of phosphate may generally be a cause of hyperphosphatemia. Hyperphosphatemia irregularly caused by a large transcellular movement of phosphate into the extracellular space, overwhelming the renal excretory capacity. Such transcellular movement frequently takes place in diabetic ketoacidosis, nontraumatic rhabdomyolysis, crush injuries, overwhelming systemic infections, tumour lysis syndrome. Hyperphosphatemia may also take place due to excessive oral phosphate administration, and, at times, with overuse of enemas carrying phosphate.
Advancements in Drug Development Likely to Boost Market Growth
Advancements in research and treatment systems are expected to drive the global hyperphosphatemia therapeutics market. For example, in 2023, it was reported that Lupin had launched Sevelamer Hydrochloride tablets (800 mg) – a medicine employed to treat hyperphosphatemia in individuals suffering from chronic kidney disease – in USA. The product had been introduced after obtaining USFDA approval.
In 2021, it was reported that individuals with chronic kidney disease on maintenance dialysis felt enhanced control of hyperphosphatemia when a dual treatment comprising tenapanor and phosphate binders was administered as against the administration of only phosphate binders or only tenapanor.
In 2020, Unicycive Therapeutics acquired Renazorb (Lanthanum Dioxycarbonate) from Spectrum Pharmaceuticals for the treatment of hyperphosphatemia in individuals with chronic kidney disease. Renazorb has exhibited distinct phosphate binding features with the potential to treat hyperphosphatemia in chronic kidney disease patients with significant patient adherence advantages including smaller and lesser pills per dose than current care standards. Such developments are expected to boost the global hyperphosphatemia therapeutics market.
In 2020, Ardelyx, Inc. announced the submission of New Drug Application (NDA) for tenapanor to USFDA for regulation of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Segmentation
By product type, the market is divided into:
- Sevelamer
- Calcium-Based Phosphate Blinders
- Iron-based Phosphate Binders
- Aluminium-based Phosphate Blinders
- Others
By form, the market is classified into:
- Capsules
- Tablet
- Syrup
On the basis of distribution channel, the market is segmented into:
- Retail Pharmacies
- Hospital Pharmacies
- Online
By region, the market is classified into:
- Europe
- North America
- Latin America
- Asia Pacific
- Middle East and Africa
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Key Industry Players in the Market
The report offers an extensive assessment of major players in the global hyperphosphatemia therapeutics market; it evaluates their capability, observes latest occurrences such as mergers and acquisitions, capacity expansions, and plant turnarounds:
- Astellas Pharma Inc.
- Akebia Therapeutics, Inc
- Lupin Limited
- Ardelyx, Inc
- Vifor Pharma Management Ltd.
- Others
Using SWOT analysis and Porter’s Five Forces model, the EMR report offers deep insights into the industry.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product type |
|
| Breakup by Form |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Hyperphosphatemia Therapeutics Market Analysis
8.1 Key Industry Highlights
8.2 Global Hyperphosphatemia Therapeutics Historical Market (2018-2023)
8.3 Global Hyperphosphatemia Therapeutics Market Forecast (2024-2032)
8.4 Global Hyperphosphatemia Therapeutics Market by Product type
8.4.1 Sevelamer
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2023)
8.4.1.3 Forecast Trend (2024-2032)
8.4.2 Calcium-Based Phosphate Blinders
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2023)
8.4.2.3 Forecast Trend (2024-2032)
8.4.3 Iron-based Phosphate Binders
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2023)
8.4.3.3 Forecast Trend (2024-2032)
8.4.4 Aluminium-based Phosphate Blinders
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2018-2023)
8.4.4.3 Forecast Trend (2024-2032)
8.4.5 Others
8.5 Global Hyperphosphatemia Therapeutics Market by Form
8.5.1 Capsules
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2023)
8.5.1.3 Forecast Trend (2024-2032)
8.5.2 Tablet
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2023)
8.5.2.3 Forecast Trend (2024-2032)
8.5.3 Syrup
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2023)
8.5.3.3 Forecast Trend (2024-2032)
8.6 Global Hyperphosphatemia Therapeutics Market by Distribution Channels
8.6.1 Hospital Pharmacies
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2023)
8.6.1.3 Forecast Trend (2024-2032)
8.6.2 Retail Pharmacies
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2023)
8.6.2.3 Forecast Trend (2024-2032)
8.6.3 Online
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2018-2023)
8.6.3.3 Forecast Trend (2024-2032)
8.7 Global Hyperphosphatemia Therapeutics Market by Region
8.7.1 North America
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2018-2023)
8.7.1.3 Forecast Trend (2024-2032)
8.7.2 Europe
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2018-2023)
8.7.2.3 Forecast Trend (2024-2032)
8.7.3 Asia Pacific
8.7.3.1 Market Share
8.7.3.2 Historical Trend (2018-2023)
8.7.3.3 Forecast Trend (2024-2032)
8.7.4 Latin America
8.7.4.1 Market Share
8.7.4.2 Historical Trend (2018-2023)
8.7.4.3 Forecast Trend (2024-2032)
8.7.5 Middle East and Africa
8.7.5.1 Market Share
8.7.5.2 Historical Trend (2018-2023)
8.7.5.3 Forecast Trend (2024-2032)
9 North America Hyperphosphatemia Therapeutics Market Analysis
9.1 United States of America
9.1.1 Market Share
9.1.2 Historical Trend (2018-2023)
9.1.3 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Market Share
9.2.2 Historical Trend (2018-2023)
9.2.3 Forecast Trend (2024-2032)
10 Europe Hyperphosphatemia Therapeutics Market Analysis
10.1 United Kingdom
10.1.1 Market Share
10.1.2 Historical Trend (2018-2023)
10.1.3 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Market Share
10.2.2 Historical Trend (2018-2023)
10.2.3 Forecast Trend (2024-2032)
10.3 France
10.3.1 Market Share
10.3.2 Historical Trend (2018-2023)
10.3.3 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Market Share
10.4.2 Historical Trend (2018-2023)
10.4.3 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Hyperphosphatemia Therapeutics Market Analysis
11.1 China
11.1.1 Market Share
11.1.2 Historical Trend (2018-2023)
11.1.3 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Market Share
11.2.2 Historical Trend (2018-2023)
11.2.3 Forecast Trend (2024-2032)
11.3 India
11.3.1 Market Share
11.3.2 Historical Trend (2018-2023)
11.3.3 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Market Share
11.4.2 Historical Trend (2018-2023)
11.4.3 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Market Share
11.5.2 Historical Trend (2018-2023)
11.5.3 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Hyperphosphatemia Therapeutics Market Analysis
12.1 Brazil
12.1.1 Market Share
12.1.2 Historical Trend (2018-2023)
12.1.3 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Market Share
12.2.2 Historical Trend (2018-2023)
12.2.3 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Market Share
12.3.2 Historical Trend (2018-2023)
12.3.3 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Hyperphosphatemia Therapeutics Market Analysis
13.1 Saudi Arabia
13.1.1 Market Share
13.1.2 Historical Trend (2018-2023)
13.1.3 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Market Share
13.2.2 Historical Trend (2018-2023)
13.2.3 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Market Share
13.3.2 Historical Trend (2018-2023)
13.3.3 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Market Share
13.4.2 Historical Trend (2018-2023)
13.4.3 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 Astellas Pharma Inc.
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 Akebia Therapeutics, Inc
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 Lupin Limited
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 Ardelyx, Inc
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 Vifor Pharma Management Ltd.
15.2.5.1 Company Overview
15.2.5.2 Product Portfolio
15.2.5.3 Demographic Reach and Achievements
15.2.5.4 Certifications
15.2.6 Others
16 Key Trends and Developments in the Market
List of Figures and Tables
1. Global Hyperphosphatemia Therapeutics Market: Key Industry Highlights, 2018 and 2032
2. Global Hyperphosphatemia Therapeutics Historical Market: Breakup by Product Type (USD Million), 2018-2023
3. Global Hyperphosphatemia Therapeutics Market Forecast: Breakup by Product Type (USD Million), 2024-2032
4. Global Hyperphosphatemia Therapeutics Historical Market: Breakup by Distribution Channel (USD Million), 2018-2023
5. Global Hyperphosphatemia Therapeutics Market Forecast: Breakup by Distribution Channel (USD Million), 2024-2032
6. Global Hyperphosphatemia Therapeutics Historical Market: Breakup by Region (USD Million), 2018-2023
7. Global Hyperphosphatemia Therapeutics Market Forecast: Breakup by Region (USD Million), 2024-2032
8. North America Hyperphosphatemia Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
9. North America Hyperphosphatemia Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
10. Europe Hyperphosphatemia Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
11. Europe Hyperphosphatemia Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
12. Asia Pacific Hyperphosphatemia Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
13. Asia Pacific Hyperphosphatemia Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Latin America Hyperphosphatemia Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
15. Latin America Hyperphosphatemia Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Middle East and Africa Hyperphosphatemia Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
17. Middle East and Africa Hyperphosphatemia Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
18. Global Hyperphosphatemia Therapeutics Market Structure
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 2199
$1799
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 3199
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 4199
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 5199
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER